Status:
COMPLETED
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Lead Sponsor:
AstraZeneca
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients w...
Eligibility Criteria
Inclusion
- Clinical diagnosis of colon or rectal cancer,
- Received prior systemic therapy for cancer,
- Cancer must have progressed during or after first treatment
Exclusion
- Prior treatment with a VEGF inhibitor,
- Poorly controlled hypertension
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT00278889
Start Date
January 1 2006
End Date
October 1 2009
Last Update
October 24 2012
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Innsbruck, Austria
2
Research Site
Vienna, Austria
3
Research Site
Wels, Austria
4
Research Site
Bonheiden, Belgium